Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC5A2 | P31639 | 5/20 | 0.35 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.35 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.34 |
| ▸ | HRAS | P01112 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22490909 | 0.83 | LGALS8 (0.42) | LGALS8PDE4DSLC5A2LGALS3KDM4E | |
| Hydrochloric Acid SCHEMBL22490928 | 0.81 | ADORA1 (0.34) | SLC5A2SLC5A1 | |
| SCHEMBL23488625 | 0.81 | LGALS3 (0.47) | LGALS8SLC6A2SLC5A2LGALS3 | |
| SCHEMBL23488453 | 0.81 | LGALS3 (0.47) | LGALS8SLC6A2SLC5A2LGALS3 | |
| SCHEMBL23488706 | 0.78 | CA2 (0.47) | LGALS8LGALS3 | |
| SCHEMBL23488312 | 0.78 | CA2 (0.47) | LGALS8LGALS3 | |
| SCHEMBL22490853 | 0.78 | NPC1 (0.39) | SLC5A2SLC5A1ALDH1A1LMNANPC1 | |
| SCHEMBL22490858 | 0.75 | PARP10 (0.47) | SLC5A2SLC5A1ALDH1A1NPC1RAB9A | |
| SCHEMBL22490929 | 0.75 | PARP10 (0.47) | SLC5A2SLC5A1ALDH1A1NPC1RAB9A | |
| SCHEMBL22490921 | 0.75 | PARP10 (0.47) | SLC5A2SLC5A1ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210170033-A1 | NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2021-06-10 | — | — | US | disclosed |
| EP-3717463-A1 | NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | Sanofi (FR) | 2020-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210170033-A1 | NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | LGALS8 61/4885PDE4D 1147/4885SLC6A2 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.